US FDA authorises company to undertake Phase 2 trial with Rayaldee (calcifediol) extended release capsules as a treatment for patients with mild-to-moderate COVID-19

The REsCue trial (166 subjects including stage 3/4 chronic kidney disease patients) will have 4 weeks of calcifediol or placebo & 2 weeks follow-up. The objective is to raise and maintain serum total 25-hydroxyvitamin D within range of 50-100 ng/mL, to mitigate COVID-19 severity


Biospace Inc.